Anti-MOG syndrome: a road to be paved

• References

• 1 Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016 Apr;15(4):307-24. https://doi.org/10.1016/j.autrev.2015.12.004
• 2 Hacohen Y, Absoud M and Waters P. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e81. https://doi.org/10.1212/NXI.20170147201701470081.
• 3 Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005;62(6):865-870. https://doi.org/10.1001/archneur.62.6.865
• 4 Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9(8):455-61. https://doi.org10.1038/nrneurol.2013.118
• 5 Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4(2):e322. https://doi.org/10.1212/NXI.20170147201701470322.
• 6 Costa BK, Passos GR, Becker J, Sato DK. MOG-igG associated optic neuritis is not multiple sclerosis. Arq Neurpsiquiatr. 2017;74(10):687-92. https://doi.org/10.1590/0004-282X20170121
• 7 Akaishi T, Nakashima I, Sato DK, Takahashi T, Fujihara K. Neuromyelitis optica spectrum disorders. Neuroimaging Clin N Am. 2017;27(2):251-65. https://doi.org/10.1016/j.nic.2016.12.010